Christopher M Roman

US Patent:

20070178087, Aug 2, 2007

Filed:

Dec 14, 2006

Appl. No.:

11/610920

Inventors:

Christopher Roman - New York NY, US
Chongmin Huan - Brooklyn NY, US

International Classification:

A61K 48/00
A61K 39/395

US Classification:

424143100, 514044000

Abstract:

Techniques for treating immune dysfunction in a patient by regulation of CD40 Ligand (CD40L) expression are provided. For example, one technique includes suppressing TFE3 and/or TFEB in the patient to thereby suppress CD40L expression in the patient. In addition, the technique may include administering a TFE3 inhibitor and/or a TFEB inhibitor for suppressing TFE3 and/or TFEB, respectively, in the patient.

US Patent:

20100211527, Aug 19, 2010

Filed:

Apr 28, 2010

Appl. No.:

12/769258

Inventors:

Christopher Roman - New York NY, US
David A. Ballard - Darien CT, US

International Classification:

G06Q 40/00
G06Q 10/00

US Classification:

705 36 R, 705 38, 705 37

Abstract:

Embodiments of the present invention, for the first time, provide methods for financing an asset management firm, by using participating debt securities as the investment engine and then collecting those interests and selling the resultant securities into a Business Development Company.

US Patent:

20200330419, Oct 22, 2020

Filed:

Nov 15, 2018

Appl. No.:

16/760146

Inventors:

- Albany NY, US
Christopher ROMAN - Brooklyn NY, US
Peiqi OU - Brooklyn NY, US

Assignee:

THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK - Albany NY

International Classification:

A61K 31/201
A61K 9/00
A61P 37/02

Abstract:

Provided is a method of reducing autoimmunity, including reducing an amount of self-reactive B cells in a subject expressing elevated levels of an autoantibody, wherein reducing includes administering 2-hydroxyoleic acid to the subject. Also provided is a method of treatment including administering 2-hydroxyoleic acid to a subject expressing elevated levels of an auto-antibody. Also provided is a method of promoting B cell tolerance, including promoting apoptosis of self-reactive B cells in a subject, wherein promoting includes administering 2-hydoxyoleic acid to the subject.